TPG's Strategic Investment in SCHOTT Poonawalla Enhances Joint Venture Growth

SCHOTT Pharma and Serum Institute of India have welcomed TPG as a new partner in their joint venture in India. TPG, a global alternative asset management firm, will acquire a 35% stake in SCHOTT Poonawalla from Serum Institute, which will retain a minority interest while SCHOTT Pharma maintains 50% ownership.

This strategic partnership aims to bolster SCHOTT Poonawalla's growth, enhancing its capabilities in drug containment and delivery solutions. With robust manufacturing infrastructure in India, the company is poised to expand its market leadership in injectables.

The partnership marks a significant milestone in SCHOTT Poonawalla's ambitions and positions TPG as a key player in supporting the joint venture's long-term goals. The transaction is pending customary closing conditions, expected within the first half of 2025.